Amgen Inc. Announces Board Changes and Executive Appointments
Ticker: AMGN · Form: 8-K · Filed: Jun 3, 2024 · CIK: 318154
| Field | Detail |
|---|---|
| Company | Amgen INC (AMGN) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, board-changes, executive-appointments
Related Tickers: AMGN
TL;DR
Amgen's board is shaking up: Bradway out, Pyott and Williams in, plus new execs and pay tweaks.
AI Summary
On May 31, 2024, Amgen Inc. filed an 8-K report detailing the departure of director Robert Bradway and the election of new directors, including David E.I. Pyott and R. Sanders Williams. The filing also announced the appointment of new officers and adjustments to compensatory arrangements for certain executives.
Why It Matters
Changes in board composition and executive roles can signal shifts in company strategy, governance, and future leadership direction.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance changes and executive appointments, which typically carry low inherent risk.
Key Players & Entities
- Amgen Inc. (company) — Registrant
- Robert Bradway (person) — Departing Director
- David E.I. Pyott (person) — Elected Director
- R. Sanders Williams (person) — Elected Director
- May 31, 2024 (date) — Date of Report
FAQ
Who has departed from Amgen's board of directors?
Robert Bradway has departed from Amgen's board of directors as of May 31, 2024.
Who has been elected to Amgen's board of directors?
David E.I. Pyott and R. Sanders Williams have been elected to Amgen's board of directors.
What other key information is disclosed in this 8-K filing?
The filing also covers the appointment of certain officers and details compensatory arrangements for certain officers.
What is the jurisdiction of incorporation for Amgen Inc.?
Amgen Inc. is incorporated in Delaware.
What is the business address of Amgen Inc.?
Amgen Inc.'s business address is One Amgen Center Drive, Thousand Oaks, California, 91320-1799.
Filing Stats: 968 words · 4 min read · ~3 pages · Grade level 9.6 · Accepted 2024-06-03 17:17:35
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value AMGN The Nasdaq Stock Mar
Filing Documents
- d827769d8k.htm (8-K) — 58KB
- 0001193125-24-153221.txt ( ) — 211KB
- amgn-20240531.xsd (EX-101.SCH) — 4KB
- amgn-20240531_def.xml (EX-101.DEF) — 13KB
- amgn-20240531_lab.xml (EX-101.LAB) — 21KB
- amgn-20240531_pre.xml (EX-101.PRE) — 14KB
- d827769d8k_htm.xml (XML) — 5KB
- Election of Directors
Item 1 - Election of Directors Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company's 2025 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death. Name Votes For Votes Against Abstain Broker Non- Votes Dr. Wanda M. Austin 393,786,163 4,305,331 691,672 64,114,405 Mr. Robert A. Bradway 372,322,447 24,802,538 1,658,181 64,114,405 Dr. Michael V. Drake 391,321,469 6,684,450 777,247 64,114,405 Dr. Brian J. Druker 394,741,846 3,279,694 761,626 64,114,405 Mr. Robert A. Eckert 377,035,518 20,940,310 807,338 64,114,405 Mr. Greg C. Garland 385,520,806 12,454,659 807,701 64,114,405 Mr. Charles M. Holley, Jr. 383,618,321 14,367,464 797,381 64,114,405 Dr. S. Omar Ishrak 394,581,111 3,432,313 769,742 64,114,405 Dr. Tyler Jacks 387,382,721 10,629,702 770,743 64,114,405 Dr. Mary E. Klotman 396,956,012 1,142,719 684,435 64,114,405 Ms. Ellen J. Kullman 389,710,003 8,345,003 728,160 64,114,405 Ms. Amy E. Miles 387,072,432 10,979,990 730,744 64,114,405 On May 31, 2024, the Board appointed Dr. Klotman, a newly elected director, to serve on the Corporate Responsibility and Compliance Committee and the Governance and Nominating Committee, effective June 1, 2024.
- Advisory Vote to Approve Our Executive Compensation
Item 2 - Advisory Vote to Approve Our Executive Compensation The advisory vote to approve our executive compensation was approved. For: 372,548,836 Against: 24,800,740 Abstain: 1,433,590 Broker Non-Votes: 64,114,405
– To Approve Our Amgen Inc. Second Amended and Restated Equity Incentive Plan
Item 3 – To Approve Our Amgen Inc. Second Amended and Restated Equity Incentive Plan Our Amgen Inc. Second Amended and Restated Equity Incentive Plan was approved. For: 377,156,504 Against: 20,285,985 Abstain: 1,340,677 Broker Non-Votes: 64,114,405
- Ratification of Selection of Independent Registered Public Accountants
Item 4 - Ratification of Selection of Independent Registered Public Accountants Ernst & Young LLP was ratified as the Company's independent registered public accountants for the fiscal year ending December 31, 2024. No Broker Non-Votes resulted from the vote on this proposal. For: 433,632,747 Against: 28,413,909 Abstain: 850,915 No other matters were submitted for stockholder action. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMGEN INC. Date: June 3, 2023 By: /s/ Jonathan P. Graham Name: Jonathan P. Graham Title: Executive Vice President and General Counsel and Secretary